false--04-30Q220220001487198P7Y00014871982021-05-012021-10-3100014871982021-12-10xbrli:shares00014871982021-10-31iso4217:USD00014871982021-04-300001487198aspu:ComputerEquipmentAndHardwareMember2021-10-310001487198aspu:ComputerEquipmentAndHardwareMember2021-04-300001487198us-gaap:FurnitureAndFixturesMember2021-10-310001487198us-gaap:FurnitureAndFixturesMember2021-04-300001487198us-gaap:LeaseholdImprovementsMember2021-10-310001487198us-gaap:LeaseholdImprovementsMember2021-04-300001487198aspu:InstructionalEquipmentMember2021-10-310001487198aspu:InstructionalEquipmentMember2021-04-300001487198us-gaap:ComputerSoftwareIntangibleAssetMember2021-10-310001487198us-gaap:ComputerSoftwareIntangibleAssetMember2021-04-300001487198us-gaap:ConstructionInProgressMember2021-10-310001487198us-gaap:ConstructionInProgressMember2021-04-300001487198aspu:IntangibleAssetsOtherThanCoursewareAndAccreditationMember2021-10-310001487198aspu:IntangibleAssetsOtherThanCoursewareAndAccreditationMember2021-04-300001487198aspu:CoursewareAndAccreditationMember2021-10-310001487198aspu:CoursewareAndAccreditationMember2021-04-30iso4217:USDxbrli:shares00014871982021-08-012021-10-3100014871982020-08-012020-10-3100014871982020-05-012020-10-310001487198us-gaap:CommonStockMember2021-07-310001487198us-gaap:AdditionalPaidInCapitalMember2021-07-310001487198us-gaap:TreasuryStockMember2021-07-310001487198us-gaap:RetainedEarningsMember2021-07-3100014871982021-07-310001487198us-gaap:AdditionalPaidInCapitalMember2021-08-012021-10-310001487198us-gaap:CommonStockMember2021-08-012021-10-310001487198us-gaap:RetainedEarningsMember2021-08-012021-10-310001487198us-gaap:CommonStockMember2021-10-310001487198us-gaap:AdditionalPaidInCapitalMember2021-10-310001487198us-gaap:TreasuryStockMember2021-10-310001487198us-gaap:RetainedEarningsMember2021-10-310001487198us-gaap:CommonStockMember2020-07-310001487198us-gaap:AdditionalPaidInCapitalMember2020-07-310001487198us-gaap:TreasuryStockMember2020-07-310001487198us-gaap:RetainedEarningsMember2020-07-3100014871982020-07-310001487198us-gaap:AdditionalPaidInCapitalMember2020-08-012020-10-310001487198us-gaap:CommonStockMember2020-08-012020-10-310001487198us-gaap:TreasuryStockMember2020-08-012020-10-310001487198us-gaap:RetainedEarningsMember2020-08-012020-10-310001487198us-gaap:CommonStockMember2020-10-310001487198us-gaap:AdditionalPaidInCapitalMember2020-10-310001487198us-gaap:TreasuryStockMember2020-10-310001487198us-gaap:RetainedEarningsMember2020-10-3100014871982020-10-310001487198us-gaap:CommonStockMember2021-04-300001487198us-gaap:AdditionalPaidInCapitalMember2021-04-300001487198us-gaap:TreasuryStockMember2021-04-300001487198us-gaap:RetainedEarningsMember2021-04-300001487198us-gaap:AdditionalPaidInCapitalMember2021-05-012021-10-310001487198us-gaap:CommonStockMember2021-05-012021-10-310001487198us-gaap:RetainedEarningsMember2021-05-012021-10-310001487198us-gaap:CommonStockMember2020-04-300001487198us-gaap:AdditionalPaidInCapitalMember2020-04-300001487198us-gaap:TreasuryStockMember2020-04-300001487198us-gaap:RetainedEarningsMember2020-04-3000014871982020-04-300001487198us-gaap:AdditionalPaidInCapitalMember2020-05-012020-10-310001487198us-gaap:CommonStockMember2020-05-012020-10-310001487198us-gaap:TreasuryStockMember2020-05-012020-10-310001487198us-gaap:RetainedEarningsMember2020-05-012020-10-31aspu:subsidiaryxbrli:pureaspu:student0001487198aspu:BSNPreLicensureProgramMember2021-10-31aspu:location0001487198aspu:RegisteredNursesRNsMember2021-10-310001487198aspu:AspenNursingMember2021-06-012021-10-310001487198aspu:AspenNursingMember2019-10-312021-10-310001487198aspu:CollateralPledgedAspenUniversityLetterOfCreditMember2021-10-310001487198aspu:CollateralPledgedBankLetterOfCreditMember2021-10-310001487198aspu:SecuredCreditLineMember2021-10-310001487198aspu:CollateralPledgedAspenUniversityLetterOfCreditMember2021-04-300001487198aspu:CollateralPledgedBankLetterOfCreditMember2021-04-300001487198aspu:SecuredCreditLineMember2021-04-300001487198aspu:StockOptionGrantsToEmployeesAndDirectorsMember2021-10-310001487198aspu:StockOptionGrantsToEmployeesAndDirectorsMember2021-04-300001487198us-gaap:RestrictedStockUnitsRSUMember2021-10-310001487198us-gaap:RestrictedStockUnitsRSUMember2021-04-300001487198us-gaap:WarrantMember2021-10-310001487198us-gaap:WarrantMember2021-04-300001487198us-gaap:RestrictedStockMember2021-10-310001487198us-gaap:RestrictedStockMember2021-04-30aspu:segment0001487198aspu:UnbilledEducationalServicesMember2021-04-300001487198aspu:CoursewareMember2021-10-310001487198aspu:CoursewareMember2021-04-300001487198aspu:AccreditationMember2021-10-310001487198aspu:AccreditationMember2021-04-300001487198aspu:CoursewareAndAccreditationMember2021-08-012021-10-310001487198aspu:CoursewareAndAccreditationMember2020-08-012020-10-310001487198aspu:CoursewareAndAccreditationMember2021-05-012021-10-310001487198aspu:CoursewareAndAccreditationMember2020-05-012020-10-310001487198aspu:HemgMember2021-07-212021-07-210001487198aspu:HemgMember2021-07-312021-07-310001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMember2018-11-050001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMember2021-08-312021-08-310001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMember2021-08-310001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMemberus-gaap:WarrantMember2021-08-310001487198us-gaap:WarrantMember2021-08-310001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMember2021-10-310001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMember2021-04-300001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMemberus-gaap:WarrantMember2018-11-050001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMemberus-gaap:WarrantMember2018-11-052018-11-050001487198us-gaap:RevolvingCreditFacilityMemberaspu:CreditFacilityAgreementMember2021-07-31aspu:plan0001487198aspu:A2018EquityIncentivePlanMember2020-12-290001487198aspu:A2018EquityIncentivePlanMember2020-12-300001487198aspu:EquityIncentivePlanMember2021-10-310001487198aspu:EquityIncentivePlanMember2021-04-300001487198aspu:A2018EquityIncentivePlanMember2021-04-300001487198aspu:A2018EquityIncentivePlanMember2021-10-310001487198us-gaap:RestrictedStockMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMember2021-05-012021-10-310001487198srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2021-08-162021-08-160001487198srt:ChiefFinancialOfficerMemberus-gaap:RestrictedStockUnitsRSUMember2021-08-160001487198us-gaap:RestrictedStockUnitsRSUMemberaspu:ChiefAcademicOfficerMember2021-08-122021-08-120001487198us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefOperatingOfficerMember2021-08-122021-08-120001487198us-gaap:RestrictedStockUnitsRSUMember2021-08-120001487198us-gaap:RestrictedStockUnitsRSUMemberaspu:A2018EquityIncentivePlanMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberaspu:A2018EquityIncentivePlanMember2021-08-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2021-07-212021-07-210001487198us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2021-07-210001487198us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2021-08-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMembersrt:ChiefExecutiveOfficerMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberaspu:EmployeesMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMemberaspu:EmployeesMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberaspu:EmployeesMembersrt:MaximumMember2021-05-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberaspu:EmployeesMember2021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2021-10-310001487198us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2020-02-042020-02-0400014871982020-02-040001487198us-gaap:RestrictedStockUnitsRSUMember2021-08-012021-10-310001487198us-gaap:RestrictedStockUnitsRSUMember2020-08-012020-10-310001487198us-gaap:RestrictedStockUnitsRSUMember2020-05-012020-10-310001487198us-gaap:WarrantMember2021-04-302021-04-300001487198us-gaap:WarrantMember2021-05-012021-10-310001487198us-gaap:WarrantMember2021-10-312021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNineMemberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNineMemberus-gaap:WarrantMember2021-10-310001487198aspu:A585Memberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:A585Memberus-gaap:WarrantMember2021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeSixZeroMemberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeSixZeroMemberus-gaap:WarrantMember2021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeElevenMemberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeElevenMemberus-gaap:WarrantMember2021-10-310001487198aspu:A699Memberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:A699Memberus-gaap:WarrantMember2021-10-310001487198aspu:LeonAndTobyCoopermanFamilyFoundationMemberus-gaap:WarrantMember2021-08-310001487198aspu:LeonAndTobyCoopermanFamilyFoundationMemberus-gaap:WarrantMember2021-08-312021-08-310001487198aspu:FormerBoardOfDirectorMemberus-gaap:WarrantMember2021-07-210001487198aspu:FormerBoardOfDirectorMemberus-gaap:WarrantMember2021-07-212021-07-210001487198aspu:FormerBoardOfDirectorMemberus-gaap:WarrantMember2021-08-012021-10-310001487198aspu:FormerBoardOfDirectorMemberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:CoopermanWarrantsMember2020-05-012020-07-310001487198aspu:CoopermanWarrantsMember2020-07-310001487198srt:DirectorMemberus-gaap:WarrantMember2019-04-100001487198srt:DirectorMemberus-gaap:WarrantMember2019-04-102019-04-100001487198srt:DirectorMemberus-gaap:WarrantMember2021-08-012021-10-310001487198srt:DirectorMemberus-gaap:WarrantMember2021-05-012021-10-310001487198aspu:StockOptionGrantsToEmployeesAndDirectorsMember2021-04-302021-04-300001487198aspu:StockOptionGrantsToEmployeesAndDirectorsMember2021-05-012021-10-310001487198aspu:StockOptionGrantsToEmployeesAndDirectorsMember2021-10-312021-10-310001487198aspu:StockOptionGrantsToEmployeesAndDirectorsMembersrt:ChiefOperatingOfficerMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeThreeMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeThreeMember2021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFourMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFourMember2021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFiveMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFiveMember2021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeSixMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeSixMember2021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeSevenMember2021-05-012021-10-310001487198aspu:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeSevenMember2021-10-310001487198us-gaap:EmployeeStockOptionMember2021-05-012021-10-310001487198us-gaap:EmployeeStockOptionMember2021-08-012021-10-310001487198us-gaap:RestrictedStockMember2021-08-012021-10-310001487198us-gaap:EmployeeStockOptionMember2020-08-012020-10-310001487198us-gaap:EmployeeStockOptionMember2020-05-012020-10-310001487198us-gaap:RestrictedStockMember2020-08-012020-10-310001487198us-gaap:RestrictedStockMember2020-05-012020-10-310001487198aspu:TuitionRevenueMember2021-08-012021-10-310001487198aspu:TuitionRevenueMember2020-08-012020-10-310001487198aspu:TuitionRevenueMember2021-05-012021-10-310001487198aspu:TuitionRevenueMember2020-05-012020-10-310001487198aspu:CourseFeeRevenueMember2021-08-012021-10-310001487198aspu:CourseFeeRevenueMember2020-08-012020-10-310001487198aspu:CourseFeeRevenueMember2021-05-012021-10-310001487198aspu:CourseFeeRevenueMember2020-05-012020-10-310001487198aspu:BookFeeRevenueMember2021-08-012021-10-310001487198aspu:BookFeeRevenueMember2020-08-012020-10-310001487198aspu:BookFeeRevenueMember2021-05-012021-10-310001487198aspu:BookFeeRevenueMember2020-05-012020-10-310001487198aspu:ExamFeeRevenueMember2021-08-012021-10-310001487198aspu:ExamFeeRevenueMember2020-08-012020-10-310001487198aspu:ExamFeeRevenueMember2021-05-012021-10-310001487198aspu:ExamFeeRevenueMember2020-05-012020-10-310001487198aspu:ServiceFeeRevenueMember2021-08-012021-10-310001487198aspu:ServiceFeeRevenueMember2020-08-012020-10-310001487198aspu:ServiceFeeRevenueMember2021-05-012021-10-310001487198aspu:ServiceFeeRevenueMember2020-05-012020-10-310001487198us-gaap:NonUsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-08-012021-10-310001487198us-gaap:NonUsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2021-05-012021-10-310001487198us-gaap:NonUsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-08-012020-10-310001487198us-gaap:NonUsMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-05-012020-10-31utr:sqft0001487198srt:MinimumMember2021-10-310001487198srt:MaximumMember2021-10-3100014871982013-02-110001487198aspu:HemgMember2015-09-2900014871982021-04-162021-04-160001487198aspu:TitleIVProgramsAspenUniversityMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-05-012021-04-300001487198aspu:TitleIVProgramsUnitedStatesUniversityMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2020-05-012021-04-300001487198us-gaap:LetterOfCreditMember2020-09-280001487198us-gaap:LetterOfCreditMember2020-08-310001487198aspu:CollateralPledgedBankLetterOfCreditMember2020-12-31
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended October 31, 2021
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
Commission file number 001-38175
aspu-20211031_g1.jpg
ASPEN GROUP, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware27-1933597
State or Other Jurisdiction of Incorporation or OrganizationI.R.S. Employer Identification No.
276 Fifth Avenue, Suite 505, New York, New York
10001
Address of Principal Executive OfficesZip Code
(646) 448-5144
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001ASPU
The Nasdaq Stock Market
(The Nasdaq Global Market)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ     No ¨
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes þ    No ¨
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes     No þ 
ClassOutstanding as of December 10, 2021
Common Stock, $0.001 par value per share
25,034,375 shares


Table of Contents
TABLE OF CONTENTS
Page Number
 



Table of Contents
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
October 31, 2021April 30, 2021
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$10,985,131 $12,472,082 
Restricted cash1,433,397 1,193,997 
Accounts receivable, net of allowance of $3,345,182 and $3,289,816, respectively
21,309,982 16,724,744 
Prepaid expenses1,577,516 1,077,831 
Other current assets20,631 68,529 
Total current assets35,326,657 31,537,183 
Property and equipment:
Computer equipment and hardware1,402,006 956,463 
Furniture and fixtures1,976,342 1,705,101 
Leasehold improvements7,057,859 5,729,324 
Instructional equipment608,894 421,039 
Software9,386,352 8,488,635 
Construction in progress900 247,767 
20,432,353 17,548,329 
Less: accumulated depreciation and amortization(6,672,208)(4,892,987)
Total property and equipment, net13,760,145 12,655,342 
Goodwill5,011,432 5,011,432 
Intangible assets, net7,907,503 7,908,360 
Courseware, net299,914 187,296 
Accounts receivable, net of allowance of $ and $625,963, respectively
 45,329 
Long-term contractual accounts receivable12,663,815 10,249,833 
Deferred financing costs117,857 18,056 
Operating lease right of use assets, net13,510,656 12,714,863 
Deposits and other assets515,569 479,212 
Total assets$89,113,548 $80,806,906 
(Continued)
The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.
1

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (CONTINUED)
October 31, 2021April 30, 2021
(Unaudited)
Liabilities and Stockholders’ Equity
Liabilities:
Current liabilities:
Accounts payable$2,102,624 $1,466,488 
Accrued expenses1,772,808 2,040,896 
Deferred revenue10,191,241 6,825,014 
Due to students3,219,643 2,747,484 
Operating lease obligations, current portion2,145,431 2,029,821 
Other current liabilities96,003 307,921 
Total current liabilities19,527,750 15,417,624 
Long-term debt5,000,000  
Operating lease obligations, less current portion17,732,483 16,298,808 
Total liabilities42,260,233 31,716,432 
Commitments and contingencies – see Note 11
Stockholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized,
0 issued and 0 outstanding at October 31, 2021 and April 30, 2021
  
Common stock, $0.001 par value; 40,000,000 shares authorized,
25,148,194 issued and 24,992,708 outstanding at October 31, 2021
25,066,297 issued and 24,910,811 outstanding at April 30, 2021
25,149 25,067 
Additional paid-in capital110,526,729 109,040,824 
Treasury stock (155,486 at both October 31, 2021 and April 30, 2021)
(1,817,414)(1,817,414)
Accumulated deficit(61,881,149)(58,158,003)
Total stockholders’ equity46,853,315 49,090,474 
Total liabilities and stockholders’ equity$89,113,548 $80,806,906 

The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.
2

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

Three Months Ended October 31,Six Months Ended October 31,
2021202020212020
Revenue$18,940,211 $16,971,045 $38,371,206 $32,136,607 
Operating expenses:
   Cost of revenue (exclusive of depreciation and amortization shown separately below)8,789,201 7,324,780 17,382,769 13,172,303 
   General and administrative11,641,312 11,285,155 22,587,789 20,078,911 
   Bad debt expense350,000 632,000 700,000 1,032,000 
   Depreciation and amortization817,234 526,357 1,596,643 1,016,981 
Total operating expenses21,597,747 19,768,292 42,267,201 35,300,195 
   Operating loss(2,657,536)(2,797,247)(3,895,995)(3,163,588)
Other income (expense):
   Interest expense(139,502)(1,529,668)(173,041)(1,985,125)
   Other (expense) income, net(49,320)(7,080)502,800 (130,378)
Total other (expense) income, net(188,822)(1,536,748)329,759 (2,115,503)
Loss before income taxes(2,846,358)(4,333,995)(3,566,236)(5,279,091)
Income tax expense 5,900 36,530 156,910 34,630 
Net loss$(2,852,258)$(4,370,525)$(3,723,146)$(5,313,721)
Net loss per share - basic and diluted$(0.11)$(0.19)$(0.15)$(0.23)
Weighted average number of common stock outstanding - basic and diluted24,957,046 22,791,503 24,935,793 22,763,235 


The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.
3

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
Three Months Ended October 31, 2021 and 2020
(Unaudited)



Common StockAdditional
Paid-In
Capital
Treasury
Stock
Accumulated
Deficit
Total
Stockholders’
Equity
SharesAmount
Balance at July 31, 202125,087,051 $25,088 $109,617,521 $(1,817,414)$(59,028,891)$48,796,304 
Stock-based compensation— — 722,158 — — 722,158 
Common stock issued for stock options exercised for cash11,655 12 33,474 — — 33,486 
Common stock issued for cashless stock options exercised30,156 30 (30)— —  
Common stock issued for vested restricted stock units19,332 19 (19)— —  
Amortization of warrant based cost— — 16,125 — — 16,125 
Warrants issued for deferred financing costs related to Credit Facility— — 137,500 — — 137,500 
Net loss— — — — (2,852,258)(2,852,258)
Balance at October 31, 202125,148,194 $25,149 $110,526,729 $(1,817,414)$(61,881,149)$46,853,315 
Common StockAdditional
Paid-In
Capital
Treasury
Stock
Accumulated
Deficit
Total
Stockholders’
Equity
SharesAmount
Balance at July 31, 202022,377,744 $22,378 $92,378,584 $(70,000)$(48,652,226)$43,678,736 
Stock-based compensation— — 1,831,548 — — 1,831,548 
Common stock issued for stock options exercised for cash502,412 502 944,830 — — 945,332 
Common stock issued for cashless stock options exercised22,339 22 (22)— —  
Common stock issued for conversion of Convertible Notes1,398,602 1,399 9,998,601 — — 10,000,000 
Common stock issued for vested restricted stock units132,109 132 (132)— —  
Amortization of warrant based cost— — 9,125 — — 9,125 
Cancellation of Treasury Stock(16,667)(17)(69,983)70,000 —  
Net loss— — — — (4,370,525)(4,370,525)
Balance at October 31, 202024,416,539 $24,416 $105,092,551 $ $(53,022,751)$52,094,216 




The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.
4

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (CONTINUED)
Six Months Ended October 31, 2021 and 2020
(Unaudited)



Common StockAdditional
Paid-In
Capital
Treasury
Stock
Accumulated
Deficit
Total
Stockholders’
Equity
SharesAmount
Balance at April 30, 202125,066,297 $25,067 $109,040,824 $(1,817,414)$(58,158,003)$49,090,474 
Stock-based compensation— — 1,264,870 — — 1,264,870 
Common stock issued for stock options exercised for cash16,752 17 56,017 — — 56,034 
Common stock issued for cashless stock options exercised30,156 30 (30)— —  
Common stock issued for vested restricted stock units34,989 35 (35)— —  
Amortization of warrant based cost— — 27,583 — — 27,583 
Warrants issued for deferred financing costs related to Credit Facility— — 137,500 — — 137,500 
Net loss— — — — (3,723,146)(3,723,146)
Balance at October 31, 202125,148,194 $25,149 $110,526,729 $(1,817,414)$(61,881,149)$46,853,315 
Common StockAdditional
Paid-In
Capital
Treasury
Stock
Accumulated
Deficit
Total
Stockholders’
Equity
SharesAmount
Balance at April 30, 202021,770,520 $21,771 $89,505,216 $(70,000)$(47,709,030)$41,747,957 
Stock-based compensation— — 2,318,658 — — 2,318,658 
Common stock issued for stock options exercised for cash917,587 918 2,214,397 — — 2,215,315 
Common stock issued for cashless stock options exercised22,339 22 (22)— —  
Common stock issued for conversion of Convertible Notes1,398,602 1,399 9,998,601 — — 10,000,000 
Common stock issued for vested restricted stock units132,109 132 (132)— —  
Common stock issued for warrants exercised for cash192,049 191 1,081,600 — — 1,081,791 
Modification charge for warrants exercised— — 25,966 — — 25,966 
Amortization of warrant based cost— — 18,250 — — 18,250 
Cancellation of Treasury Stock(16,667)(17)(69,983)70,000 —  
Net loss— — — — (5,313,721)(5,313,721)
Balance at October 31, 202024,416,539 $24,416 $105,092,551 $ $(53,022,751)$52,094,216 




The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.





5

Table of Contents


ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Six Months Ended October 31,
 20212020
Cash flows from operating activities:
Net loss$(3,723,146)$(5,313,721)
Adjustments to reconcile net loss to net cash used in operating activities:
Bad debt expense700,000 1,032,000 
Depreciation and amortization1,596,643 1,016,981 
Stock-based compensation1,264,870 2,318,658 
Amortization of warrant based cost27,583 18,250 
Amortization of debt discounts 1,550,854 
Amortization of debt issue costs18,056 147,695 
Amortization of deferred financing costs19,643  
Modification charge for warrants exercised 25,966 
Loss on asset disposition36,442  
Lease benefit(63,099) 
Tenant improvement allowances received from landlords816,591  
Changes in operating assets and liabilities:
Accounts receivable(7,699,220)(8,246,180)
Prepaid expenses(520,685)(654,268)
Other receivables 23,097 
Other current assets47,901 (273,767)
Accounts receivable, other45,329  
Deposits and other assets(15,357)(171,303)
Accounts payable636,136 838,421 
Accrued expenses(268,088)1,282,983 
Due to students472,159 (301,619)
Deferred revenue3,366,227 4,915,504 
Other current liabilities(211,918)(286,372)
Net cash used in operating activities(3,453,933)(2,076,821)
Cash flows from investing activities:
Purchases of courseware and accreditation(149,751)(11,375)
Purchases of property and equipment(2,699,901)(2,233,348)
Net cash used in investing activities(2,849,652)(2,244,723)
Cash flows from financing activities:
Borrowings under the Credit Facility5,000,000  
Proceeds from stock options exercised56,034 2,215,315 
Proceeds from warrants exercised 1,081,792 
Net cash provided by financing activities5,056,034 3,297,107 

(Continued)
The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.

6

Table of Contents

ASPEN GROUP, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS (CONTINUED)
(Unaudited)
Six Months Ended October 31,
20212020
Net decrease in cash, cash equivalents and restricted cash$(1,247,551)$(1,024,437)
Cash, cash equivalents and restricted cash at beginning of period13,666,079 17,906,765 
Cash, cash equivalents and restricted cash at end of period$12,418,528 $16,882,328 
Supplemental disclosure cash flow information:
Cash paid for interest$98,904 $285,749 
Cash paid for income taxes$157,552 $38,608 
Supplemental disclosure of non-cash investing and financing activities:
Common stock issued for conversion of Convertible Notes$ $10,000,000 
Warrants issued as part of Credit Facility$137,500 $ 

The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the accompanying consolidated balance sheet to the total amounts shown in the accompanying unaudited consolidated statements of cash flows:
October 31, 2021April 30, 2021
Cash and cash equivalents $10,985,131 $12,472,082 
Restricted cash1,433,397 1,193,997 
Total cash, cash equivalents and restricted cash$12,418,528 $13,666,079 


The accompanying condensed notes are an integral part of these unaudited consolidated financial statements.
7

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)


Note 1. Nature of Operations
Overview
Aspen Group, Inc. ("AGI") is an education technology holding company. AGI has two subsidiaries, Aspen University Inc. ("Aspen University"), organized in 1987, and United States University Inc. ("United States University" or "USU").
All references to the “Company”, “AGI”, “Aspen Group”, “we”, “our” and “us” refer to Aspen Group, Inc., unless the context otherwise indicates.
AGI leverages its education technology infrastructure and expertise to allow its two universities, Aspen University and United States University, to deliver on the vision of making college affordable again. Because we believe higher education should be a catalyst to our students’ long-term economic success, we exert financial prudence by offering affordable tuition that is one of the greatest values in higher education.  AGI’s primary focus relative to future growth is to target the high growth nursing profession.
Since 1993, Aspen University has been nationally accredited by the Distance Education Accrediting Council (“DEAC”), an institutional accrediting agency recognized by the United States Department of Education (the “DOE”), through January 2024.
Since 2009, USU has been institutionally accredited by WASC Senior College and University Commission. (“WSCUC”).
Both universities are qualified to participate under the Higher Education Act of 1965, as amended (HEA) and the Federal student financial assistance programs (Title IV, HEA programs). USU has a provisional certification resulting from the ownership change of control in connection with the acquisition by AGI on December 1, 2017.
COVID-19 Update
Nursing students represented 87% or 12,442 of the Company’s total student body of 14,318 students at the end of the second quarter of fiscal 2022. Of the 12,442 nursing students, 2,500 are BSN Pre-Licensure students located across our four metro locations (Phoenix, Austin, Tampa and Nashville). The remaining 9,942 nursing students are licensed registered nurses (RNs) studying to earn an advanced degree (RN to BSN, MSN, MSN-FNP or DNP degree programs). Therefore, these 9,942 post-licensure nursing students represent 69% of the Company’s total student body and are the population of AGI students primarily affected by the COVID-19 pandemic.

Starting in the second half of June 2021 and continuing through October 2021, the Company saw lower course starts than seasonally expected among our RN student body. For example, at Aspen University, course starts among RNs from June through October increased by approximately 3% year-over-year. By comparison, over the previous two full fiscal years (Fiscal Year 2021 and Fiscal Year 2020), course starts among RNs at Aspen University increased by an average of approximately 10% year-over-year.

In terms of new student enrollments, the Company saw enrollment growth on a quarterly sequential basis in all BSN Pre-Licensure metros as these prospective students continue to communicate a strong desire to enter the nursing profession. However, aggregate enrollments among RNs at both Aspen University and United States University were relatively flat on a quarterly sequential basis.

We cannot be certain what impact the Delta variant and other variants will have on the Company’s results as we progress through the second half of fiscal 2022.

Basis of Presentation
Interim Financial Statements
8

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

The interim consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations for the three and six months ended October 31, 2021 and 2020, our cash flows for the six months ended October 31, 2021 and 2020, and our financial position as of October 31, 2021 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.
Certain information and disclosures normally included in the notes to the annual consolidated financial statements have been condensed or omitted from these interim consolidated financial statements. Accordingly, these interim consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the fiscal year ended April 30, 2021 as filed with the SEC on July 13, 2021. The April 30, 2021 consolidated balance sheet is derived from those statements.
Note 2. Significant Accounting Policies
Basis of Presentation and Consolidation

The Company prepares its consolidated financial statements in accordance with U.S. generally accepted accounting principles ("GAAP").
The consolidated financial statements include the accounts of AGI and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.
A full listing of our significant accounting policies is described in Note 2 “Summary of Significant Accounting Policies” of our Annual Report on Form 10-K for the fiscal year ended April 30, 2021 as filed with the SEC on July 13, 2021.
Accounting Estimates
Management of the Company is required to make certain estimates, judgments and assumptions during the preparation of its consolidated financial statements in accordance with GAAP. These estimates, judgments and assumptions impact the reported amounts of assets, liabilities, revenue and expenses and the related disclosure of contingent assets and liabilities. Actual results could differ from those estimates.
Significant estimates in the accompanying consolidated financial statements include the allowance for doubtful accounts and other receivables, the valuation of lease liabilities and the carrying value of the related right-of-use ("ROU") assets, depreciable lives of property and equipment, amortization periods and valuation of courseware, intangibles and software development costs, valuation of goodwill, valuation of loss contingencies, valuation of stock-based compensation and the valuation allowance on deferred tax assets.
Cash, Cash Equivalents, and Restricted Cash
For the purposes of the consolidated statements of cash flows, the Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents.
Restricted cash as of October 31, 2021 of $1,433,397 consists of $1,173,525 which is collateral for letters of credit for the Aspen University and USU facility operating leases, $9,872 which is collateral for a letter of credit for USU required to be posted based on the level of Title IV funding in connection with USU's most recent Compliance Audit, and a $250,000 compensating balance under a secured credit line.
Restricted cash as of April 30, 2021 of $1,193,997 consisted of $934,125 which is collateral for letters of credit for the Aspen University and USU facility operating leases, $9,872 which is collateral for a letter of credit for USU required to be posted based on the level of Title IV funding in connection with USU's most recent Compliance Audit, and a $250,000 compensating balance under a secured credit line.
9

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

Concentration of Credit Risk
The Company maintains its cash in bank and financial institution deposits that at times may exceed federally insured limits of $250,000 per financial institution. The Company has not experienced any losses in such accounts from inception through October 31, 2021. As of October 31, 2021 and April 30, 2021, the Company maintained deposits exceeding federally insured limits by approximately $11,765,690 and $13,005,537, respectively, held in two separate institutions.
Revenue Recognition and Deferred Revenue
The Company follows Accounting Standards Codification 606 (ASC 606). ASC 606 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This ASC also requires additional disclosure about the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer purchase orders, including significant judgments.
Revenue consists primarily of tuition and course fees derived from courses taught by the Company online and in-person as well as from related educational resources and services that the Company provides to its students. Under ASC 606, tuition and course fee revenue is recognized pro-rata over the applicable period of instruction and are not considered separate performance obligations.  Non-tuition related revenue and fees are recognized as services are provided or when the goods are received by the student. (See Note 8) Students may receive discounts, scholarships, or refunds, which gives rise to variable consideration. The amounts of discounts or scholarships are applied to individual student accounts when such amounts are awarded. Therefore, the tuition is reduced directly by these discounts or scholarships from the amount of the standard tuition rate charged.
Deferred revenue represents the amount of tuition, fees, and other student payments received in excess of the portion recognized as revenue and it is included in current liabilities in the accompanying consolidated balance sheets. Other revenue may be recognized as sales occur or services are performed.
Net Loss Per Share
Net loss per share is based on the weighted average number of shares of common stock outstanding during each period. Options to purchase 992,050 and 1,214,473 shares of common stock, 899,103 and 549,972 restricted stock units ("RSUs"), warrants to purchase 449,174 and 374,174 shares of common stock, and unvested restricted stock of 8,224 and 8,224 were outstanding at October 31, 2021 and April 30, 2021, respectively.
All shares mentioned above were not included in the computation of diluted net loss per share because the effects would have been anti-dilutive. The options, warrants, RSUs and unvested restricted stock are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share of common stock when their effect is dilutive.
Segment Information
The Company operates in one reportable segment as a single educational delivery operation using a core infrastructure that serves the curriculum and educational delivery needs of its online and campus students regardless of geography. The Company's chief operating decision makers, its Chief Executive Officer, Chief Operating Officer and Chief Academic Officer, manage the Company's operations as a whole.
Recent Accounting Pronouncement Not Yet Adopted
ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which significantly changes how entities will measure credit losses for most financial assets, including accounts receivable. ASU No. 2016-13 will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. On November 15, 2019, the FASB delayed the effective date of Topic 326 for certain small public companies and other private companies until fiscal years
10

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

beginning after December 15, 2022 for SEC filers that are eligible to be smaller reporting companies under the SEC’s definition, as well as private companies and not-for-profit entities. The Company is currently evaluating the new guidance and has not yet determined whether the adoption of the new standard will have a material impact on its consolidated financial statements or the method of adoption.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation.
The Company has concluded that based on industry practices, the preferred presentation for cash received in advance for unearned tuition and stipends should be reclassified from "restricted cash" to "cash and cash equivalents." The cash balance of $3,958,793 for funds held for students for unbilled educational services that were received from Title IV and non-Title IV programs at April 30, 2021, which was previously included in "restricted cash" in the accompanying consolidated balance sheet, was reclassified to "cash and cash equivalents" to align with the current year presentation. There is no impact to total current assets included in accompanying consolidated balance sheet at April 30, 2021. The restricted cash balance at April 30, 2021, now includes letters of credit and a compensating balance under a secured credit line of $1,193,997.
Note 3. Property and Equipment
As property and equipment reach the end of their useful lives, the fully expired assets are written off against the associated accumulated depreciation and amortization.
When assets are disposed of before reaching the end of their useful lives both the recorded cost of the fixed asset and the corresponding amount of accumulated depreciation is reversed. Any remaining difference between the two is recognized as either other income or expense.
Software consisted of the following:
October 31,
2021
April 30,
2021
Software$9,386,352 $8,488,635 
Accumulated amortization(4,284,129)(3,444,325)
Software, net$5,102,223 $5,044,310 
Depreciation and amortization expense for property and equipment and software is summarized below:
Three Months Ended October 31,Six Months Ended October 31,
2021202020212020
Depreciation and amortization expense:
Property and equipment, excluding software$367,475 $164,204 $718,848 $327,774 
Software$428,143 $346,653 $839,804 $661,760 
Note 4. Courseware and Accreditation
As courseware and accreditation reach the end of their useful life, they are written off against the accumulated amortization. There was no expense impact for such write-offs for the three and six months ended October 31, 2021 and 2020.
11

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

Courseware and accreditation consisted of the following:
October 31,
2021
April 30,
2021
Courseware$557,973 $408,222 
Accreditation59,350 59,350 
617,323 467,572 
Accumulated amortization(317,409)(280,276)
Courseware and accreditation, net$299,914 $187,296 
Amortization expense for courseware and accreditation is summarized below:
Three Months Ended October 31,Six Months Ended October 31,
2021202020212020
Amortization expense$21,185 $10,516 $37,133 $22,463 
Amortization expense is included in "Depreciation and amortization" in the unaudited consolidated statements of operations.
Note 5. Secured Note and Accounts Receivable
On March 30, 2008 and December 1, 2008, Aspen University sold courseware pursuant to marketing agreements to Higher Education Management Group, Inc. (“HEMG”), which was then a related party and principal stockholder of the Company. As discussed in Note 11, the Company and Aspen University sued HEMG seeking to recover sums due under the agreements. Ultimately, the Company and Aspen University obtained a favorable default judgment, and as a result received a distribution from the bankruptcy trustee court of $498,120, which is included in "other (expense) income, net" in the accompanying unaudited consolidated statements of operations for the six months ended October 31, 2021. Due to the bankruptcy of HEMG, the Company also wrote off a net receivable of $45,329 in the same period.
Note 6. Long-term Debt
Credit Facility
On November 5, 2018, the Company entered into a loan agreement (the “Credit Facility Agreement”) with the Leon and Toby Cooperman Family Foundation (the “Foundation”). The Credit Facility Agreement provided for a $5,000,000 revolving credit facility (the “Credit Facility”) evidenced by a revolving promissory note (the “Revolving Note”). Borrowings under the Credit Facility Agreement bear interest at 12% per annum. Interest payments are due monthly through the term of the Credit Facility.
On August 31, 2021, the Company extended the Credit Facility Agreement with the Foundation by one year from November 4, 2021 to November 4, 2022. In conjunction with the extension of the Facility, the Company drew down $5,000,000 of funds from the Facility at 12% interest per annum due November 4, 2022.
Additionally, on August 31, 2021, the Company issued to the Foundation warrants, as an extension fee, to purchase 50,000 shares of the Company’s common stock exercisable for five years from the date of issuance at the exercise price of $5.89 per share. The fair value of the warrants is $137,500 and is being amortized over the 14-month line of credit period. The fair value of the warrants are treated as deferred financing costs in the accompanying consolidated balance sheets at October 31, 2021 to be amortized over the term of the Credit Facility. Total unamortized costs at October 31, 2021 were $117,857. See Note 7 for additional information related to these warrants.
At October 31, 2021 and April 30, 2021, there were $5,000,000 and no outstanding borrowings, respectively, under the Credit Facility.
The Credit Facility Agreement contains customary representations and warranties and events of default. Pursuant to the Loan Agreement and the Revolving Note, all future or contemporaneous indebtedness incurred by the Company, other than indebtedness expressly permitted by the Credit Facility Agreement and the Revolving Note, will be subordinated to the Facility.
12

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

On March 6, 2019, the Company amended and restated the Credit Facility Agreement (the “Amended and Restated Facility Agreement”) and the Revolving Note. The Amended and Restated Facility Agreement provides among other things that the Company’s obligations thereunder are secured by a first priority lien in certain deposit accounts of the Company, all current and future accounts receivable of Aspen University and USU, certain of the deposit accounts of Aspen University and USU and all of the outstanding capital stock of Aspen University and USU.
Pursuant to the Credit Facility Agreement, on November 5, 2018 the Company issued to the Foundation warrants to purchase 92,049 shares of the Company’s common stock exercisable for five years from the date of issuance at the exercise price of $5.85 per share which were deemed to have a relative fair value of $255,071 (the "2018 Cooperman Warrants"). These warrants were exercised on June 8, 2020. The fair value of the warrants along with the upfront Facility fee were treated as debt issue cost assets to be amortized over the term of the loan, as the facility has not been drawn on. As a result of the aforementioned note extension, the remainder of the unamortized costs of $9,722 were written off during the quarter ended October 31, 2021. Total unamortized costs at October 31, 2021 and April 30, 2021 were $0 and $18,056, respectively.
Note 7. Stockholders’ Equity
AGI maintains two stock-based incentive plans: the 2012 Equity Incentive Plan (the “2012 Plan”) and 2018 Equity Incentive Plan (the “2018 Plan”) that provides for the grant of shares in the form of incentive stock options, non-qualified stock options, restricted shares, stock appreciation rights and RSUs to employees, consultants, officers and directors.

On December 30, 2020, the Company held its Annual Meeting of Shareholders at which the shareholders voted to amend the 2018 Plan to increase the number of shares of common stock available for issuance under the 2018 Plan from 1,100,000 to 1,600,000 shares.

As of October 31, 2021 and April 30, 2021 there were 171,459 and 549,739 shares remaining available for future issuance under the 2012 and the 2018 Plans, respectively.

Restricted Stock
As of October 31, 2021, there were 8,224 unvested shares of restricted common stock outstanding. During the six months ended October 31, 2021, there were no new restricted stock grants, forfeitures, vested stock or expirations. Total unrecognized compensation expense related to the unvested shares as of October 31, 2021 was $7,018, and is expected to be recognized over a weighted-average period of approximately 0.17 years.

Restricted Stock Units
A summary of the Company’s RSU activity during the six months ended October 31, 2021 is presented below:
Restricted Stock UnitsNumber of SharesWeighted Average Grant Price
Unvested balance outstanding, April 30, 2021549,972 $6.58 
Granted412,792 6.16 
Forfeits(28,841)9.80 
Vested(34,820)6.15 
Expired  
Unvested balance outstanding, October 31, 2021899,103 $5.38 

Of the 412,792 RSUs granted during the six months ended October 31, 2021, 410,000 RSUs correspond to executive compensation grants summarized below.

On August 16 2021, the Compensation Committee approved a 125,000 RSU grant to the Company’s newly hired Chief Financial Officer as part of the employment agreement. The grant has a grant date fair value of $725,000 based on a closing stock price of $5.80 per share. On August 12, 2021, the Compensation Committee approved individual grants of 80,000 RSUs
13

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

to the Company’s Chief Operating Officer and Chief Academic Officer. The grants have a total grant date fair value of $1.0 million based on a closing stock price of $6.48 per share.

The three executive grants discussed above are under the Company’s 2018 Equity Incentive Plan and are set to vest annually over a period of three years and are subject to continued employment as an officer of the Company on each applicable vesting date. The amortization expense related to these grants for the three months ended October 31, 2021 was $146,817 and is included in "general and administrative expense" in the accompanying consolidated statement of operations.

On July 21, 2021, as part of a new employment agreement, the Compensation Committee approved a 125,000 RSU grant to the Company's Chief Executive Officer under the Company's 2018 Equity Incentive Plan. The grant has a grant date fair value of $873,750 based on a closing stock price of $6.99 per share. As stipulated in the grant, vesting is subject to continued employment with the Company and will occur in full on the date the Company files with the SEC a quarterly or annual report on Forms 10-Q or 10-K, as applicable, which reflects the Company's reported net income on a GAAP basis. The Company expects this condition to be met in the fourth quarter of Fiscal 2022 and is amortizing the expense over one year through July 2022 (the filing date of the Form 10-K for Fiscal Year 2022). The Company will continue to assess the performance condition at each reporting period. If the RSUs do not vest within three years from the July 21, 2021 effective date, they will be forfeited. The amortization expense related to this grant for the three and six months ended October 31, 2021 was $72,813 and $218,438, respectively, which is included in general and administrative expense in the consolidated statements of operations.

The remaining 2,792 RSU grants during the six months ended October 31, 2021 were granted to employees and have a grant date fair value that ranges from $4.92 to $6.50 per share, or a total of $16,456, vesting annually over three years and subject to continued employment on each applicable vesting date.

Of the 899,103 unvested RSUs outstanding at October 31, 2021, there are 195,000 RSUs remaining from the February 4, 2020 executive grant. These RSUs vest four years from the grant date, if each applicable executive is still employed by the Company on the vesting date and subject to accelerated vesting for all RSUs if the closing price of the Company’s common stock is at least $12 for 20 consecutive trading days. On the grant date, the closing price of the Company's common stock on The Nasdaq Global Market was $9.49 per share. The amortization expense related to these transactions for the three and six months ended October 31, 2021 and 2020, was approximately $112,155 and $224,311, and $111,211 and $1.5 million, respectively, which is included in general and administrative expense in the consolidated statements of operations.
At October 31, 2021, total unrecognized compensation expense related to unvested RSUs is $4,839,604 and is expected to be recognized over a weighted-average period of approximately 1.57 years.
Warrants
The Company estimates the fair value of warrants utilizing the Black-Scholes pricing model, which is dependent upon several variables such as the expected term, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected term and expected dividend yield rate over the expected term. The Company believes this valuation methodology is appropriate for estimating the fair value of warrants issued to directors which are subject to ASC Topic 718 requirements. These amounts are estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. The Company recognizes expense on a straight-line basis over the vesting period of each warrant issued.
14

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

A summary of the Company’s warrant activity during the six months ended October 31, 2021 is presented below:
WarrantsNumber of
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Balance Outstanding, April 30, 2021374,174 $6.37 1.90$ 
Granted75,000 $6.23 4.80— 
Exercised $ — — 
Surrendered $ — — 
Expired $ — — 
Balance Outstanding, October 31, 2021449,174 $6.35 1.96$ 
Exercisable, October 31, 2021424,174 $6.31 1.80$ 

OUTSTANDING WARRANTSEXERCISABLE WARRANTS
Exercise
Price
Weighted
Average
Exercise
Price
Outstanding
No. of
Warrants
Weighted
Average
Exercise
Price
Weighted
Average
Remaining Life
In Years
Exercisable
No. of
Warrants
$4.89 $4.89 50,000 $4.89 2.4450,000 
$5.85 $5.85 50,000 $5.85 4.8450,000 
$6.00 $6.00 100,000 $6.00 2.35100,000 
$6.87 $6.87 224,174 $6.87 0.73224,174 
$6.99 $6.99 25,000 
 449,174   424,174 

On August 31, 2021, the Compensation Committee approved the issuance of warrants to the Leon and Toby Cooperman Family Foundation as an extension fee in connection with the $5 million revolving line of credit. The warrants allow for the purchase of 50,000 shares of the Company’s common stock and have an exercise price of $5.85. The warrants have an exercise period of five years from the August 31, 2021 issuance date and will terminate automatically and immediately upon the expiration of the exercise period. The fair value of the warrants is $137,500 and is being amortized over the 14-month line of credit period. The Company has recognized $19,643 of amortization expense in connection with the fair value of the warrants for the three months ending October 31, 2021, which is included in "interest expense" in the accompanying consolidated statement of operations.

On July 21, 2021, the Compensation Committee approved warrants to a former member of the Board of Directors for the purchase of 25,000 shares of the Company's common stock with an exercise price of $6.99 per share. The warrants have an exercise period of five years from the July 21, 2021 issuance date and vest annually over a three year period subject to continued service on the Company's Advisory Board on each applicable vesting date. The warrants will terminate automatically and immediately upon the expiration of the exercise period. The fair value of the warrants is $84,000 and is being amortized over the three year vesting period. The Company has recognized $7,000 and $9,333 of amortization expense in connection with the fair value of the warrants for the three and six months ending October 31, 2021, respectively, which is included in “general and administrative” expense in the accompanying consolidated statement of operations.
During the three months ended July 31, 2020, there was a warrant modification and acceleration charge of $25,966 related to the exercise of 192,049 warrants by the Leon and Toby Cooperman Family Foundation, which was included in “other (expense) income, net” in the accompanying consolidated statement of operations.
On April 10, 2019, the Company issued warrants to an advisory board member for services to purchase 50,000 shares of the Company's common stock with an exercise price of $4.89 per share. The warrants have an exercise period of five years from the April 10, 2019 issuance date and vest annually over a three year period. The warrants will terminate automatically and immediately upon the expiration of the exercise period. The fair value of the warrants is $109,500 and is being amortized over
15

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)

the three year vesting period. The Company has recognized $9,125 and $18,250 of amortization expense in connection with the fair value of the warrants for the three and six months ending October 31, 2021 and 2020, respectively, which is included in “general and administrative” expense in the accompanying consolidated statement of operations.
Stock Option Grants to Employees and Directors

The Company estimates the fair value of share-based compensation utilizing the Black-Scholes option pricing model, which is dependent upon several variables such as the expected option term, expected volatility of the Company’s stock price over the expected term, expected risk-free interest rate over the expected option term and expected dividend yield rate over the expected option term. The Company believes this valuation methodology is appropriate for estimating the fair value of stock options granted to employees and directors which are subject to ASC Topic 718 requirements. These amounts are estimates and thus may not be reflective of actual future results, nor amounts ultimately realized by recipients of these grants. The Company recognizes compensation on a straight-line basis over the requisite service period for each award.

The Company utilizes the simplified method to estimate the expected life for stock options granted to employees. The simplified method was used as the Company does not have sufficient historical data regarding stock option exercises. The expected volatility is based on historical volatility. The risk-free interest rate is based on the U.S. Treasury yields with terms equivalent to the expected life of the related option at the time of the grant. Dividend yield is based on historical trends. While the Company believes these estimates are reasonable, the compensation expense recorded would increase if the expected life was increased, a higher expected volatility was used, or if the expected dividend yield increased.

A summary of the Company’s stock option activity for employees and directors during the six months ended October 31, 2021, is presented below:
OptionsNumber of
Shares
Weighted
Average
Exercise
Price
Weighted
Average
Remaining
Contractual
Term
Aggregate
Intrinsic
Value
Balance Outstanding, April 30, 20211,214,473 $6.24 1.88$204,719 
Granted  — — 
Exercised(216,752)5.77 — — 
Forfeited(4,419)4.61 — — 
Expired(1,252)2.76 — — 
Balance Outstanding, October 31, 2021
992,050 $6.61 1.56$172,313 
Exercisable, October 31, 2021
928,457 $6.72 1.51$161,584 

Of the 216,752 options exercised for 46,908 common shares during the six months ended October 31, 2021, 200,000 were cashless options exercised by the Company’s Chief Operating Officer in September 2021. As part of this cashless transactions, 30,156 net shares were issued and 169,844 were retained by the Company.
During the three and six months ended October 31, 2021 and 2020, the Company received proceeds from the exercise of stock options for cash of $33,486 and $56,034 and $945,332 and $2,215,315, respectively.
16

Table of Contents
ASPEN GROUP, INC. AND SUBSIDIARIES
CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
October 31, 2021
(Unaudited)


OUTSTANDING OPTIONSEXERCISABLE OPTIONS
Exercise
Price
Weighted
Average
Exercise
Price
Outstanding
Number of
Options
Weighted
Average
Exercise
Price
Weighted
Average
Remaining Life
In Years
Exercisable
Number of
Options
$3.24 to $4.38
$3.82 179,264 $3.81 0.78166,597 
$4.50 to $5.20
$4.94 153,944 $5.00 1.99111,019 
$5.95 to $6.28
$5.95 28,000 $5.95 0.8128,000 
$7.17 to $